Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine

Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest a major regulatory milestone – the European Medicines Agency’s recommendation to approve its first-of-its-kind combination influenza and COVID-19 vaccine, mCOMBRIAX.

After spiking sharply around 10:00 AM EST on the news, the stock has since reversed course and is trading at $51.06, down $0.65 (-1.27%) as of 9:51 AM EST, illustrating the turbulent sentiment surrounding the embattled vaccine maker. The intraday reversal reflects the broader uncertainty investors still hold toward Moderna’s path to profitability, even as the company notches meaningful pipeline progress.

Europe Clears Moderna’s Combo Vaccine in a Historic First

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for mCOMBRIAX, Moderna’s mRNA-based combination vaccine targeting both influenza and COVID-19 in adults aged 50 and older.

The recommendation is a historic one, mCOMBRIAX would become the first flu-plus-COVID combination vaccine to receive such an opinion from the regulatory body, and if formally approved by the European Commission, it would become Moderna’s fourth marketed product across the EU and European Economic Area countries. The EC decision is widely expected to follow the CHMP’s positive recommendation.

The approval recommendation was backed by data from a Phase 3 clinical trial involving roughly 8,000 adults across two age cohorts, those aged 65 and older, and adults between 50 and 64. The study met all primary endpoints demonstrating non-inferior immune responses and generated statistically significantly stronger immune responses against three influenza strains and against SARS-CoV-2 across both age groups.

The safety profile was characterized as acceptable, with most adverse reactions being mild to moderate in severity and consistent with the comparator vaccines used in the trial.

Join our Telegram group and never miss a breaking digital asset story.

MRNA Stock Brief: Live Price, Trends, and Key Metrics

As of 9:51 AM EST on February 27, 2026, MRNA shares are trading at $51.06, down $0.65 (-1.27%) on the session, having given back a sharp spike that briefly pushed the stock toward $52.50 following the EU news earlier in the morning.

The intraday chart tells the story of a classic “buy the rumor, sell the news” dynamic, with the stock unable to hold its gains despite the positive regulatory headline. Despite today’s pullback, MRNA remains up over 76% year-to-date, dramatically outpacing the S&P 500’s near-flat performance over the same period.

On the fundamentals side, Moderna carries a market cap of approximately $20.35 billion and reported Q4 FY2025 revenue of $678 million, beating estimates while posting a loss of $2.11 per share, better than the forecast of -$2.60. The company holds $5.8 billion in cash with a modest debt-to-equity ratio of 15.09%, providing a financial buffer as it works toward profitability.

Analyst sentiment remains divided: the average 12-month price target of $42.05 sits below the current trading price, though Piper Sandler recently raised its target to $69 while maintaining an Overweight rating. The FDA’s acceptance of Moderna’s biologics license application for its standalone flu vaccine mRNA-1010, with a PDUFA review date of August 5, 2026, remains a key upcoming catalyst to watch.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.